Clinical trial · Observational
Prospective Study for Molecular Biomarkers and Spatial Transcriptomics of Nasopharyngeal Carcinoma
NCT05912582CI-TRIAL-00099713not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This clinical research aims to explore potential biomarkers and validate molecular signatures' predictive and prognostic value in nasopharyngeal carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Intensity modulated radiation therapy (IMRT) combined with chemotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Observation Group
- interventionNames
- Radiation: Intensity modulated radiation therapy (IMRT) combined with chemotherapy
Primary outcomes (1)
- measure
- major pathological response
- timeFrame
- 3 months after radiation therapy
Secondary outcomes (2)
- measure
- Progression-free Survival
- timeFrame
- 2 years after radiation therapy
- measure
- Overall Survival
- timeFrame
- 2 years after radiation therapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with newly histologically confirmed nasopharyngeal carcinoma 2. No evidence of distant metastasis (M0) 3. Written informed consent Exclusion Criteria: Treatment with palliative intent
References
Publications (0)
Data not yet available
No reference posted for this study.